­
Publikasi Scopus FKUI 2021 per tanggal 31 Oktober 2021 (739 artikel)

Publikasi Scopus FKUI 2021 per tanggal 31 Oktober 2021 (739 artikel)

Aggarwal B., Jones P.W., Yunus F., Lan L.T.T., Boonsawat W., Ismaila A., Ascioglu S.
23007797900;26121204500;57194486277;55570089700;35608231000;15127439100;57222578443;
Direct healthcare costs associated with management of asthma: comparison of two treatment regimens in Indonesia, Thailand and Vietnam
2021
Journal of Asthma
Regional Respiratory Medical Affairs, GSK, Singapore, Singapore; Global Specialty & Primary Care, GSK, Brentford, Middlesex, United Kingdom; Institute for Infection and Immunity, St George?s University of London, London, United Kingdom; Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, University of Indonesia-Persahabatan National Respiratory Center Hospital, Jakarta, Indonesia; Faculty of Medicine, University of Medicine and Pharmacy, Ho Chi Minh City, Viet Nam; Division of Respiratory System, Department of Internal Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand; Value Evidence and Outcomes, GSK, Collegeville, PA, United States; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada; Clinical Sciences R&D, GSK, Singapore, Singapore
Aggarwal, B., Regional Respiratory Medical Affairs, GSK, Singapore, Singapore; Jones, P.W., Global Specialty & Primary Care, GSK, Brentford, Middlesex, United Kingdom, Institute for Infection and Immunity, St George?s University of London, London, United Kingdom; Yunus, F., Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, University of Indonesia-Persahabatan National Respiratory Center Hospital, Jakarta, Indonesia; Lan, L.T.T., Faculty of Medicine, University of Medicine and Pharmacy, Ho Chi Minh City, Viet Nam; Boonsawat, W., Division of Respiratory System, Department of Internal Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand; Ismaila, A., Value Evidence and Outcomes, GSK, Collegeville, PA, United States, Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada; Ascioglu, S., Clinical Sciences R&D, GSK, Singapore, Singapore
Objective: Daily inhaled corticosteroid (ICS) and long-acting beta-2-agonist (LABA) combinations comprising either regular maintenance therapy with ICS/LABA plus as-needed short-acting beta-2-agonist (SABA) or ICS-formoterol combinations used as maintenance and reliever therapy (MART) are recommended for moderate asthma. This analysis compares the direct costs of twice-daily fluticasone propionate/salmeterol (FP/salm) and budesonide/formoterol MART in three Southeast Asian countries. Methods: A literature review identified three randomized trials in patients with asthma (? 12 years) comparing regular twice-daily FP/salm with as-needed SABA versus MART in moderate asthma: AHEAD (NCT00242775/17 countries/2309 patients), COMPASS (AstraZeneca study SD-039-0735/16 countries/3335 patients), and COSMOS (AstraZeneca study SD-039-0691/16 countries/2143 patients). Economic analyses, conducted from a healthcare sector perspective (medication costs + healthcare utilization costs), applied unit costs from countries where healthcare costs are publicly available: Indonesia, Thailand and Vietnam. Results are expressed in British pound sterling (GBP/patient/year). Results: Annual exacerbation rates were low and differences between treatment strategies were small (range, FP/salm: 0.31?0.38, MART: 0.24?0.25) although statistically significant in favor of MART. Total average (minimum-maximum) direct costs (in GBP/patient/year) across the three studies were ?187 (?137??284), ?158 (?125??190), and ?151 (?141??164) for those who used FP/salm, and ?242 (?217??267), ?284 (?237??340) and ?266 (?224??315) for MART in Indonesia, Thailand and Vietnam, respectively. On average, total direct costs/patient/year with FP/salm were 22.8%, 44.6% and 43.0% lower than with MART for Indonesia, Thailand and Vietnam, respectively. Conclusions: In the three countries evaluated, total treatment costs with regular twice-daily FP/salm were consistently lower than with budesonide/formoterol MART due to lower direct healthcare costs. ? 2021 GlaxoSmithKline. Published with license by Taylor & Francis Group, LLC.
healthcare utilization; ICS/LABA; maintenance therapy; medication; Southeast Asia
Taylor and Francis Ltd.
2770903
Article
Q2
687
7267